Does model for end-stage liver disease (MELD) require modification?

Area of Science:

• Hepatology
• Transplantation Medicine
• Medical Prognostics

Background:

• The Model for End-stage Liver Disease (MELD) score is a standard prognostic tool for cirrhotic patients awaiting liver transplantation.
• It assesses serum bilirubin, serum albumin, and the International Normalized Ratio (INR) to predict short-term survival.

Purpose of the Study:

• To evaluate the accuracy of the MELD score in predicting survival for liver transplant candidates and recipients.
• To identify limitations of the MELD score and propose modifications for improved prognostic accuracy.

Main Methods:

• Analysis of MELD score components (serum bilirubin, albumin, INR) in cirrhotic patients.
• Comparison of MELD score predictions with actual survival outcomes in pre- and post-liver transplantation cohorts.

Main Results:

• The MELD score accurately predicts 3-month survival in approximately 85% of cirrhotic patients awaiting liver transplantation.
• MELD-Na is recommended for improved accuracy in a subset of patients where MELD is a poor predictor.
• The MELD score demonstrates limited accuracy in predicting survival after liver transplantation.

Conclusions:

• The MELD score is a valuable tool for pre-transplant survival prediction but has limitations.
• Modifications, such as downgrading the score for recipient age and disease recurrence risk, are recommended to enhance post-transplant survival prediction.